Summary of the release, highlighting how this FDA clearance will allow BrainsWay to increase patient pool to include patients who have comorbid anxiety and depression symptoms, and who have historically not responded to drug and/or talk therapy.
BrainsWay receives FDA clearance for noninvasive comorbid anxiety, depression treatment
Comments